賽生藥業(6600.HK):今日掛牌上市 商業化進程快
格隆匯3月3日丨領先生物製藥公司賽生藥業(6600.HK)今日掛牌上市,截至發稿報19.1港元,最新市值逼近130億港元。該公司是一家擁有產品和商業化集成平台的領先生物製藥公司,戰略上專注於中國最大並且發展迅速的醫療需求未滿足領域。相較於市面上眾多未盈利生物科技類企業,賽生藥業的商業化進程較快,已經擁有8款已上市產品正在銷售,在研管線亦在不斷補充產品組合新鮮血液,擁有1款擬上市產品,8款在研產品,主要用於治療腫瘤和重症感染疾病。都是人類患病概率高的領域,受眾人羣廣,市場空間大。 約10%募資比例投向將用於招聘、擴大銷售與營銷網絡以及商業及開發基礎設施,公司在上市之後的商業化能力,憑藉影響力的增強,預期將得到快速的提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.